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MEDICATION ADHERENCE STUDIES
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Objectives: Non-adherence is associated with poorer health outcomes and 
increased costs. This study evaluated the impact of a community pharmacist 
medication adherence consultation on health care costs and the risk of hospitali-
zation. MethOds: Patients initiating therapy within 16 drug classes were offered 
face-to-face or telephonic consultations by a Walgreens pharmacist between 
2/7/2013 – 10/6/2013. Consultation included motivational interviewing focused on 
fitting medication-taking behavior into patients’ daily routine, and removing bar-
riers to adherence. Patients were assigned to two groups according to the intensity 
of consultation: no consultations (NC) and ≥ 1 consultations received (CR). Patients 
were linked deterministically to the IMS Health PharMetrics Plus database such that 
6 months of pharmacy and medical claims data pre and post their index date could 
be analyzed. Cost differences from the pre to post-index periods were compared 
between NC and CR groups, using difference in differences estimation in a GLM 
model, controlling for demographic and clinical confounders. Results: CR patients 
(n= 58,449) and NC patients (n= 53,870) had similar age (48.2 vs. 47.7 years), gender 
(59.0% vs. 57.7% female) and disease burden (0.61 vs. 0.58 for Charlson Comorbidity 
Index, CCI). CR patients incurred significantly lower pre- to post-index GLM-adjusted 
total health care costs (-$266/-4.3% lower, p= 0.001), comprised of lower inpatient 
(-$231, p= 0.009), lower pharmacy (-$43, p< 0.0001), and similar outpatient costs (-$36, 
p= 0.279); and had a lower probability of hospitalization (OR: 0.92, 95% CI: 0.86, 0.98, 
p= 0.009). CR patients with a CCI equal to 1-2 realized the greatest cost savings 
(-$688, p= 0.001) compared to patients with CCI= 0 (-$106, p= 0.051), and CCI≥ 3 ($575, 
p= 0.293). cOnclusiOns: Patients receiving structured pharmacist consultations 
focused on improving medication adherence were shown to have significantly lower 
health care costs and risk of hospitalization. Ongoing studies will explore underly-
ing relationships between program participation, adherence, and impact on health 
outcomes and costs.
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Objectives: We have previously demonstrated that full adherence with ACE-
Inhibitors (ACEI) or statins in a post-myocardial infarction (MI) population is 
associated with lower rate of cardiovascular (CV) events compared to partial- or 
non-adherence. Herein, we sought to determine the direct medical costs attributable 
to partial- and non- adherence to these therapies. MethOds: Data on CV events 
and resource utilization were collected through a retrospective, nested cohort study 
in a large US insurer database. We also analyzed two national files for physician 
and non-physician unit cost weighted averages of CV events (stroke, MI, athero-
sclerosis or angina), procedures (revascularization and CV tests) and visits (emer-
gency room and outpatient CV visits). We estimated per person cost differences 
between adherence groups and the sensitivity of the Results using weighted and 
unweighted averages. A third-party payer economic perspective was adopted; all 
costs were expressed in 2014$. Results: The estimated per patient weighted aver-
age annual cumulative medical costs were $5,153 for adherent, $6,470 for partially-
adherent and $6,767 for non-adherent patients. This difference was mainly driven 
by a lower rate of CV events and revascularizations for adherent patients. Applying 
referenced unweighted averages, we estimated that the MI reference unit cost was 
$4,325 higher than the weighted average cost (p< 0.001); the CV test unit cost was 
$1,010 higher than the weighted average cost (p= 0.001). Using national prevalence 
data for incident MIs and medication adherence, we project that full adherence 
may lead to annual savings of $98.2 million and $100.9 million over partial- and 
non-adherence, respectively. cOnclusiOns: Full adherence to statins and ACEI 
was associated with reduced per patient monthly direct medical costs of $109.7 and 
$134.4 over partial- and non-adherence. Using unweighted, rather than weighted, 
averages overestimated the economic impact, indicating the importance of data 
type in such analyses. Full adherence to guideline-recommended therapies has 
tremendous cost-saving implications.
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bAcKGROund: The sizable fraction of the elderly adults who are left without Part D 
coverage indicates there are potential barriers in taking up Part D, including infor-
mation barriers and economical barriers. Few studies have examined how cost-
related medication nonadherence (CRN) affected the willingness of taking up Part D 
among elderly adults using national representative data. Objectives: To estimate 
the impact of self-reported CRN on the decision of taking up Medicare Part D among 
Medicare beneficiaries age 65 and above who did not have Part D coverage in 2006 
incorporating the effect of complex sample survey design. MethOds: This retro-
spective cross-sectional study used data from the 2006 Health and Retirement Study 
database (2006 HRS). Information on patient demographics, social and economic 
factors and health insurance coverage were obtained by survey. The dual-eligible 
beneficiaries were excluded due to automatically enrollment. A total of 5,826 eligible 
risk of TM by hormone receptor status adjusting for age. Results: Among the 
86255 women with invasive breast cancer, 38621 (45%) underwent TM, 10261 (12%) 
were Her2 positive, and 9512 (11%) were Black. For Black women with T1 tumors, 
after adjusting for age, the odds of TM were 1.3 (95% CI 1.1, 1.6) times higher for 
estrogen receptor (ER)(+) and Her2(+) tumors compared to women who were ER(+)
Her2(-), 1.4 (95% CI 1.1, 1.8) times higher for ER(+)Her2(+) compared to ER(-)Her2(-), 
and 1.4 (95% CI 1.0, 1.8) times higher for ER(-)Her2(+) compared to ER(-)Her2(-). For 
White women with T1 tumors, after adjusting for age, the odds of TM were 1.4 (95% 
CI 1.3, 1.5) times higher for ER(+)Her2(+) compared to ER(+)Her2(-), 1.1 (95% CI 1.0, 
1.2) times higher for ER(+) Her2(+) compared to ER(-)Her2(-), and 1.7 (95% CI 1.5, 1.9) 
times higher for ER(-)Her2(+) compared to ER(-)Her2(-). Similar Results were seen 
for stage T2 tumors. cOnclusiOns: For both Black and White women with early 
stage tumors, Her2 positivity predicts TM. Further research should investigate the 
role of Her2 positivity in influencing the surgical decision-making of early stage 
breast cancer patients.
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Objectives: Although European Medicines Association approved 21 biosimilars 
from 2007-2014; the Food and Drug Administration approved its first, filgrastim, 
in 2014. Regulatory approvals require pharmacokinetic/pharmacodynamic stud-
ies and efficacy/safety trials with fewer patients and shorter durations than for 
reference biologicals. Cost savings are 20%-30%. However, uptake of biosimilars 
may be delayed since clinicians and decision makers may have concerns about 
clinically-relevant differences in effectiveness, safety, and/or immunogenicity. 
Therefore, our objective was to review published literature regarding studies 
of effectiveness, safety, immunogenicity, and costs of biosimilars versus refer-
ence biologicals. MethOds: We searched electronic databases using the term 
“biosimilar pharmaceuticals” as a major topic, with filters for English language 
and human species. Our inclusion criteria were: study design for comparison of 
biosimilars and data included in Results. We excluded editorials, in vitro stud-
ies, and descriptive summaries. Results: We identified 174 articles. Inclusion/
exclusion criteria left 19 equivalence studies for the following: epoetins (n= 4, 
21.1%), filgrastims (n= 10, 52.6%), monoclonal antibodies (MABs) (n= 2, 10.5%), 
tumor necrosis factor blockers and MABs (n= 1, 5.3%), and interferon (n= 2, 10.5%). 
The median sample size was 104, but there were 3 large studies (n= 6177, n= 904, 
n= 606). Fifteen studies (79.0%) reported comparative effectiveness. Most studies 
also reported on safety (n= 12, 63.2%), immunogenicity (n= 6, 33.6%), and/or costs 
(n= 3, 15.8%). Cost studies included a budget impact model regarding potential sav-
ings from adopting biosimilars versus reference biologics for rheumatic disease, 
a model of cost savings comparing biosimilar versus reference epoetins, and a 
survey of uptake and associated cost savings from various biosimilar filgrastims 
across European Union countries. cOnclusiOns: Most current published data 
on biosimilar equivalence focus primarily on effectiveness, evaluate relatively 
small numbers of patients, and report minimal data on safety, immunogenicity, or 
cost savings. To increase uptake, biosimilar manufacturers and regulators should 
consider conducting post-marketing surveillance research to provide additional 
data on safety, immunogenicity and costs.
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Objectives: Consensus on the evidence required to recommend clinical pharma-
cogenomic testing is unclear. A formal assessment of pharmacogenomic evidence 
levels in relation to other clinical interventions, such as avoiding drug-drug inter-
actions (DDI), may be helpful for policymakers. The objective of this study was 
to quantitatively compare the evidence levels of two contested drug-attenuating 
interactions with clopidogrel antiplatelet therapy, and assess the value of obtain-
ing additional evidence to inform clinical practice guidelines. MethOds: We 
developed analogous value of information (VOI) decision models for: (1) avoidance 
of proton pump inhibitors (PPIs) in clopidogrel patients, and (2) pharmacogenomic-
guided antiplatelet selection, both versus no intervention. Interaction-specific 
parameters and model structures were the only dissimilarities. We calculated 
the expected value of obtaining perfect information (EVPI) per patient, and the 
expected population value of obtaining additional information through future 
studies (EVSI). Results: Current evidence for interaction-1 was slightly less 
uncertain (a 20% probability of making a non-optimal recommendation) than for 
interaction-2 (23%). The relative risk for cardiovascular death (conferred by con-
comitant PPI use in interaction-1, and reduced-function CYP2C19 alleles in interac-
tion-2) was the greatest source of uncertainty in both models. The expected value 
of perfect information for interaction-1 was $139 per patient, compared to $242 per 
patient for interaction-2. In simulated 10,000-patient clinical trials, the expected 
population value of future research for interaction-1 was $2 million, versus $110 
million for interaction-2. cOnclusiOns: The evidence levels for clopidogrel DDI 
and pharmacogenomic effects appear to be fairly similar. However, the value of 
conducting future research on clopidogrel pharmacogenomics is higher because 
of greater uncertainty about the impact of pharmacogenomic testing on cardio-
vascular mortality. Our findings imply that evidence-based clinical guidelines 
for DDI and pharmacogenomic effects should be generally similar with regard to 
direction and strength of recommendation. This contrasts to some degree with 
current guidelines and drug labeling.
